Rheumatic Fever Treatment Market is estimated with a CAGR of 5.2% during the forecast period - by PMI
June 11, 2021 10:35 ET
|
PMI
Covina, CA, June 11, 2021 (GLOBE NEWSWIRE) -- Rheumatic Fever Treatment Market is estimated with a CAGR of 5.2% during the forecast period. Rheumatic fever is an infectious inflammatory condition...
Global Eating Disorder Therapy market – 35.6 Million Eating Disorder cases Worldwide - by PMI
March 02, 2021 10:35 ET
|
PMI
Covina CA, March 02, 2021 (GLOBE NEWSWIRE) -- {{DATELINECITY_DATE_GLOBENEWSWIRE_BUG} The Global Eating Disorder Therapy market accounted for US$457.5Mn in 2020 and is estimated to be 2030 US$...
Global Oral Solid Dosage Excipients Market estimated to be US$ 5.9 billion by 2030 with a CAGR of 7.9% during the forecast period - by PMI
March 02, 2021 10:05 ET
|
PMI
Covina CA, March 02, 2021 (GLOBE NEWSWIRE) -- Global Oral Solid Dosage Excipients Market accounted for US$ 2.8 billion in 2020 and is estimated to be US$ 5.9 billion by 2030 and is anticipated to...
Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Company’s Abemaciclib at Virtual San Antonio Breast Cancer Symposium 2020
December 03, 2020 10:20 ET
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision...
ELI LILLY AND COMPANY ALERT: Bragar Eagel & Squire, P.C. is Investigating Eli Lilly and Company on Behalf of Eli Lilly Stockholders and Encourages Investors to Contact the Firm
October 20, 2020 19:00 ET
|
Bragar Eagel & Squire
NEW YORK, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Eli Lilly and Company...
Sermonix Doses First Patient in Phase 2 Clinical Trial Collaboration Studying Lasofoxifene in Combination With Eli Lilly and Company’s Abemaciclib
October 13, 2020 09:30 ET
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision...
Sermonix Pharmaceuticals to Collaborate With Eli Lilly and Company in Studying Combination of Lasofoxifene and Lilly’s CDK 4 and 6 Inhibitor, Abemaciclib, in Metastatic Breast Cancer
July 08, 2020 10:00 ET
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, July 08, 2020 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision...
T1D Exchange Co-Founder Dana Ball to Step Down as CEO
May 11, 2018 08:30 ET
|
T1D Exchange
BOSTON, May 11, 2018 (GLOBE NEWSWIRE) -- T1D Exchange, a patient-centered research organization dedicated to accelerating therapies and improving care for people with type 1 diabetes (T1D), today...
Innovators From 17 Countries Vie for $250,000 in Cash and In-Kind Support to Advance Diabetes Care in the 2018 Diabetes Innovation Challenge
March 20, 2018 08:15 ET
|
T1D Exchange
BOSTON, March 20, 2018 (GLOBE NEWSWIRE) -- T1D Exchange, a nonprofit research and collaboration organization dedicated to accelerating novel treatments to improve the care of people living with type...